The protein disulfide isomerase (PDI) gene family is a protein family classically characterized by endoplasmic reticulum (ER) localization and isomerase and redox activity. ERp57, a prominent multifunctional member of the PDI family, is detected at various levels in multiple cellular localizations outside of the ER. ERp57 has been functionally linked to a host of physiological processes and numerous studies have demonstrated altered expression and aberrant functionality of ERp57 in association with diverse pathological states. Here, we summarize available knowledge of ERp57's functions in subcellular compartments and the roles of dysregulated ERp57 in various diseases toward an emphasis on the potential utility of therapeutic development of ERp57.
bonds; further study of PDI revealed additional functionality as a component of enzyme systems prolyl-4-hydroxylase and triacylglycerol transfer protein (Freedman et al., 1994) . As the PDI family has expanded, the study of additional members has revealed that PDI proteins comprise a diverse family with members varying in localization and functionality.
ERp57 (also known as PDIA3, ERp60, GRP58, and 1,25D3-MARRS; encoded by PDIA3) is a prominent member of the PDI family that has attracted significant attention from researchers. ERp57 was first detected as a stress-responsive protein with upregulated expression following glucose depletion-induced cellular stress (Lee, 1981) . Originally erroneously identified as a phospholipase C (Bennett, Balcarek, Varrichio, & Crooke, 1988) , ERp57 was later demonstrated exhibit redox and protein disulfide isomerase activity (Bourdi et al., 1995; Charnock-Jones, Day, & Smith, 1996) . ERp57, unlike most PDI family members, does not contain a C-terminal ER retention motif capable of effectively limiting localization to the ER lumen and ERp57 has been found in many different subcellular locations (Hatahet & Ruddock, 2009; Raykhel et al., 2007) .
ERp57 is expressed ubiquitously at an organ systems level but with variability in physiological expression levels within different tissues. Available evidence indicates multiple distinct functional roles of ERp57 under physiological and disease states. De-regulation of ERp57 has been implicated in multiple pathologies including neurodegenerative diseases (Altmann et al., 2016; Gonzalez-Perez et al., 2015; Hetz et al., 2005; Nardo et al., 2011; Tohda, Urano, Umezaki, Nemere, & Kuboyama, 2012; Torres et al., 2015; Xu, Liu, Chen, & Liang, 2013) , metabolic diseases (Dihazi et al., 2013; Nardai et al., 2005; Wilding et al., 2015) , musculoskeletal system conditions (Doroudi, Plaisance, Boyan, & Schwartz, 2015; Wang et al., 2010; Yang, Yu, Kim, Lee, & Park, 2016) , airway inflammation (Hoffman et al., 2016) , and cancer (Choe et al., 2015; Gaucci, Altieri, Turano, & Chichiarelli, 2013; Wise, Duhachek-Muggy, Qi, Zolkiewski, & Zolkiewska, 2016 ) and ERp57 expression level has been evaluated as a useful biomarker for diagnosis and/or prognosis in several conditions (Choe et al., 2015; Leys et al., 2007; Liao et al., 2011; Nardo et al., 2011; Torres et al., 2015) . This review aims to provide a summation of current knowledge relating to multiple functions of ERp57 in various cellular compartments, highlight the possible clinical applications of targeting ERp57, and provide perspectives on the studies currently necessary to further understanding of this protein.
The structure and localization of ERp57
TRX-like domains of the PDI proteins are present as catalytically active domains (a or a′) or inactive domains (b or b′). Each domain contains a TRX-like fold with alternating α-helices and β-strands (Ferrari & Soling, 1999; Kozlov et al., 2006; Silvennoinen et al., 2004) . ERp57 is structurally similar to PDI, containing four TRX-like domains (a-b-b′-a ′; Fig. 1 ), with matching redox active CGHC motifs and similar reduction potentials of the enzymes' dual catalytic domains (Hatahet & Ruddock, 2009; Kozlov et al., 2006) . The catalytically inactive central domains, b and b′, have a vital role in the specific functionality of ERp57 in binding and protein folding.
Flanking the TRX-like domains of ERp57 are an N-terminal amino acid signal sequence and a C-terminal sequence. The N-terminal signal sequence directs initial ER localization while the C-terminus contains a QDEL ER retention/retrieval motif (Khanal & Nemere, 2007) . ERp57 is classically considered an ER resident protein but also contains a nuclear location sequence and stimulation with various macrophage differentiation-inducing agents and cellular stressors is able to induce ERp57 transfer from cytoplasm to nucleus (Grillo et al., 2006; Grindel, Rohe, Safford, Bennett, & Farach-Carson, 2011; Wu et al., 2010) . ERp57 has also been detected on cell surface (Khanal & Nemere, 2007) , as well as in mitochondria (He, Shi, Guo, & Chai, 2014; Ozaki, Yamashita, & Ishiguro, 2008) . Proposed explanations for presentation of ERp57 outside of the ER include proteolysis of the retention sequence, formation of complexes that block recognition of the retention sequence, and saturation of the ER retention machinery . Regardless of the mechanism(s) underlying ERp57's subcellular localization, it is clear that the enzyme's activity is not limited to those attributed to classical ER-resident proteins.
The biological functions of ERp57
The multiple functions and the binding partners of ERp57 in various cellular compartments are briefly summarized in Table 1 and Fig. 2 , and described in detail below.
In ER
The ER has multiple functions critical to cell survival and signaling including quality control during protein maturation as the site of sequester and modification of newly synthesized and misfolded proteins, steroid and phospholipid synthesis, maintenance of Ca 2+ homeostasis, endoplasmic-reticulum-associated protein degradation (ERAD) and modulation of proliferation and apoptosis through the unfolded protein response (UPR). ERp57 participates in many of the functions carried out within this organelle. Implementation of murine loss-of-function models has powerfully demonstrated the significance of ERp57's function in the ER. Homozygous knockout of PDIA3, the gene that encodes ERp57, is embryonic lethal; heterozygous PDIA3 knockouts are viable but exhibit increased ER stress and activation of the UPR leading to elevated ER-stress-induced apoptosis and inflammation (Linz et al., 2015; Wang et al., 2010) . ERp57 participates in protein folding through its protein disulfide isomerase activity in association with the P-domain of paralogous molecular chaperone molecules calreticulin and calnexin (CRT and CLNX respectively) (Bourdi et al., 1995; Charnock-Jones et al., 1996; Molinari & Helenius, 1999; Oliver et al., 1997 Oliver et al., , 1999 Torres et al., 2015; Wise et al., 2016) . CRT/CLNX assists in protein quality control by selectively binding misfolded proteins and preventing their secretion from the A: ERp57 has a total 505 amino acids, and consists of 4 domains, a-b-b′-a′, together with a N-terminal signal sequence and QDEL C-terminal ER retention/retrieval motif. The a and a′ domains are shown in blue while b and b′ are shown in yellow. Both a and a′ domains hold a thioredoxin-like active site and each contains a redox active CGHC catalytic sequence. b and b′ domains contain binding sites for calreticulin and calnexin. The amino acid positions of these domains and sequences are indicated in the panel B: The X-ray crystal structure of the b and b′ domains of Erp57 (Kozlov et al., 2006 ) reveals a rigid asymmetrical three-dimensional structure. Each domain features four α helices that encase a central β sheet (from NCBI structure database MMDB: 41,000 viewed using Cn3D). (Bourdi et al., 1995; Charnock-Jones et al., 1996; Molinari & Helenius, 1999; Oliver, Roderick, Llewellyn, & High, 1999; Oliver, van der Wal, Bulleid, & High, 1997; Torres et al., 2015; Wise et al., 2016) 
Endoplasmic reticulum
Stabilization of the MHC class I PLC Mediation of disulfide linkage between ERp57 and tapasin in the PLC core (Dick, Bangia, Peaper, & Cresswell, 2002; Dong, Wearsch, Peaper, Cresswell, & Reinisch, 2009; Garbi, Tanaka, Momburg, & Hammerling, 2006; Lindquist, Jensen, Mann, & Hämmerling, 1998; Peaper & Cresswell, 2008; Wearsch & Cresswell, 2008 Participates in degradation of RAR-α Unclear -ERp57 and RAR-α co-localize in the ER under inhibition of proteasome-mediated degradation. ERp57: RAR-α interaction in degradation may be mediated through CRT (Zhu, Santos, & Kim, 2010 ) Plasma membrane
Participates in sperm and egg fusion Unclear -ERp57 postulated to promote thiol-disulfide exchange mediated conformational activation of membrane proteins (Ellerman, Myles, & Primakoff, 2006; Liu et al., 2014 Liu et al., , 2015 Plasma Membrane
Immunogenicity signal Cytosolic complex formation between ERp57 and CRT is required for CRT's presentation on the membrane (Obeid, 2008) . Plasma membrane
Rapid response to 1α,25(OH)2D3 ERp57 acts as a membrane receptor for 1α,25(OH)2D3 (Boyan, Chen, & Schwartz, 2012; Boyan, Wong, Fang, & Schwartz, 2007; Chen et al., 2016; Gaucci et al., 2016; Nemere, Garcia-Garbi, et al., 2012; Richard, Farach-Carson, Rohe, Nemere, & Meckling, 2010; Sequeira et al., 2012; Song et al., 2013 ) Plasma membrane
Indirect influence upon ectodomain shedding of TNFR1 ERp57: 1α,25(OH)2D3 binding activates PKC which triggers ADAM10 translocation to the cell surface where the metalloproteinase mediates ectodomain shedding of TNFR1 (Yang et al., 2015) Plasma membrane
Associates with STAT3 plasma membrane rafts potentially to sequester STATs Sehgal, Guo, Shah, Kumar, & Patel, 2002) unknown Plasma membrane
Protects EGF signaling In MDA-MB-468 breast cancer cells and cervical cancer HeLa cells, ERp57protects EGFR signaling through a positive effect on receptor autophosphorylation, possibly through ERp57-mediated conformational change of the receptor or through an indirect influence, though the mechanism remains undefined . Plasma membrane
Modulation of gastric acid secretion Positive modulates basal activity of H+, K+ ATPase in gastric parietal cells through a incompletely described mechanism involving interaction with αHK and carried out independent of ERp57's catalytic sites and chaperone capacity (Fujii et al., 2013) 
Plasma membrane
Stimulates sodium and chloride uptake In distal convoluted tubule kidney cells ERp57 associates with the NCC and positively effects NCC activity. The mechanism underlying ERp57's influence on NCC activity is unclear in mammalian cells. In yeast, this interaction occurs at the NCC COOH-terminal domain and a role of ERp57 in mediating insertion and removal of the NCC at the apical plasma membrane (Wyse, Ali, & Ellison, 2002 ) Mitochondria Apoptotic signaling Mitochondrial ERp57 associates with and may stabilize mitochondrial μ-calpain as a foldase of the large subunit of mitochondrial μ-calpain (Ozaki et al., 2008 ) Mitochondria Stimulation of mitochondrial calcium uptake ERp57 regulates expression of MCU (He et al., 2014) .
Cytosol
Associates with STAT3 complexes ERp57 associates with cytosolic statosome complexes during traffic between the membrane and nucleus. The nature of ERp57's interaction with these complexes is unclear Cytosol
Promotes assembly and activity of mTOR, potentially participates in upstream signal detection ERp57 exerts a positive effect on the assembly of mTOR complexes, particularly mTORC1, through an undefined mechanism. ERp57 interacts with the kinase domain of mTORC1 and positively modulates basal activity of the complex -possibly due to EPp57's stimulation of mTORC1 catalytic activity. A loss of mTORC1 response to insulin following ERp57 knockdown suggests that ERp57 may also participate in upstream signal detection (Ramirez-Rangel et al., 2011; Sarbassov & Sabatini, 2005) . Cytosol Required for RAR-α's translocation from the cytosol to the nucleus. Complex formation between ERp57:RAR-α:ATRA-RAR-α is required for the nuclear appearance of RAR-α possibly through a mechanism dependent on ERp57's thiol oxidoreductase activity (Zhu et al., 2010) . Cytosol Potential role monocyte/macrophage differentiation Correlative evidence suggests that ERp57 may associate with cytosolic NFκβ as a chaperone to mediate transport to the nucleus upon 1α,25(OH)2D3 stimulation of NB4 promyelocytic leukemia cells (Wu et al., 2010) . Nucleus Potential regulation of gene expression during monocyte/macrophage differentiation Correlative evidence from cells stimulated to undergo monocyte/macrophage differentiation, wherein ERp57 and NFκβ rapidly translocate to the nucleus, suggests that ERp57 and NFκβ potentially act within a protein complex to drive non-genomic expression of ERp57 and NFκβ target genes (Grindel et al., 2011; Rohe, Safford, Nemere, & Farach-Carson, 2005; Wu et al., 2010 (Aureli et al., 2013; Grillo et al., 2006) .
Nucleus
Signaling sites of modified DNA ERp57 associates with a nuclear protein complex that targets to modified DNA (Krynetski, Krynetskaia, Bianchi, & Evans, 2003) wherein ERp57 phosphorylates H2AX, indicating a role of ERp57 in early response to DNA damage and potentially targeting ER. Characterization of ERp57's b-b′ domains has revealed the structure of ERp57's lectin P-domain binding site responsible for interaction between ERp57 and CRT/CLNX (Kozlov et al., 2006) . Lysine and arginine residues in the b′ domain of ERp57, essential for interaction with CRT/ CLNX, lend to an overall positive surface charge facilitatory to the binding of the negatively charged lectin P-domain; the b domain provides an additional surface-accessible lysine residue contributory to the stability of interaction (Kozlov et al., 2006) . The binding of CRT/CLNX and ERp57 brings CRT/CRLNX-bound substrates in contact with the ERp57 active isomerase sites (Kozlov et al., 2006) . ERp57 also plays an indirect but important role in infection and immune response as a component of the major histocompatibility complex (MHC) class I peptide-loading complex (PLC) (Lindquist et al., 1998; Wearsch & Cresswell, 2008 ). ERp57 appears to serve a structural function in the PLC core through disulfide linkage of Cys57, the Nterminal residue in the catalytic motif of the ERp57 a domain, with Cys95 of tapasin; structural characterization has further revealed that non-covalent interactions at the a and a′ active sites of ERp57 stabilize the heterodimer (Dick et al., 2002; Dong et al., 2009) . Notably, however, the redox activity of ERp57 is not required for the interaction (Peaper & Cresswell, 2008) . Significant reduction in stable interactions of MHC class I molecules with the loading complex and reduced presentation of antigens following targeted deletion of ERp57 in murine B cells illustrate the importance of ERp57 to MHC PLC formation and function (Garbi et al., 2006) . These structural and in vitro studies indicate that ERp57 indirectly participates in peptide-loading, MHC class I compound binding, and glycoprotein folding through association with tapasin and stabilization of the MHC class I PLC.
ERp57 has also been implicated in viral infection. Independent of CRT/CLNX binding, ERp57 isomerizes disulfide bonds of the Simian virus 40 (SV40) capsid proteins, which constitutes an initial uncoating of the virus preceding translocation to the cytosol (Schelhaas et al., 2007) . Similarly, ERp57 mediated isomerization of disulfide bonds has been proposed as a key step of viral infection by murine polyomavirus (Walczak & Tsai, 2011) . Ca 2+ is an integral second messenger that regulates a wide variety of cellular processes through rapid signal integration and response as well as changes to gene transcription on a longer time scale (Berridge, Bootman, & Roderick, 2003 (Prins et al., 2011) . Further, ERp57 negatively regulates the activity of sarco/endoplasmic reticulum Ca
2+
-ATPase 2b (SERCA2b) through a mechanism dependent upon Ca 2+ and the catalytic activity of the ERp57 active domains (Li & Camacho, 2004) . The dissociation of ERp57 from SERCA2b upon internal calcium store depletion is accompanied by reduction of SERCA2b and increased activation of the pump.
These interactions demonstrate ERp57's regulatory role in ER Ca 2+ flux and homeostasis. In sum, ERp57 has well-established functionality as a resident, oxidoreductive chaperone in the ER. ERp57 participates in protein folding mediated through interaction with CRT/CLNX; loss of ERp57 leads to activation of the UPR and ER-stress induced inflammation and cell death. Recently, studies have indicated that the physiological role of ERp57 in protein folding may be hijacked to facilitate viral infection in certain conditions. Further, through CRT-mediated interaction with SERCA2b and through binding STIM1, ERp57 functions in regulation of internal Ca 2+ stores. ERp57 is also a vital structural component of the MHC class I PLC. These functions, tying ERp57 to multiple crucial processes within the ER, have been widely reported and are relatively well-understood; in other cellular locations, the enzyme's redox and binding properties are thought to similarly drive functionality, however, the effects of ERp57 outside of the ER are not yet fully defined.
At the membrane
The thiol-disulfide interchange capability of ERp57 also plays an important role in aspects of ERp57 function in membrane localities through establishment of inter-and intramolecular disulfide bonds. For example, ERp57 is upregulated during gamete maturation and is necessary for efficient fusion of sperm and egg; likely through thioldisulfide exchange-mediated conformational activation of membrane proteins (Ellerman et al., 2006; Liu et al., 2014 Liu et al., , 2015 . Protein:protein interactions that do not involve the catalytic sites of ERp57 are likewise important at the membrane. Complex formation between ERp57 and CRT on the cytosolic side of the plasma membrane is required for CRT translocation to the membrane; exposure of CRT on the cell membrane is a required for the immunogenic death observed in tumor cells (Obeid, 2008; Panaretakis et al., 2008) .
ERp57 also acts as a direct binding partner of proteins at the cell membrane to mediate signaling cascades in multiple cell types. Identification of ERp57 as a membrane-associated receptor for the active form of vitamin D3, 1α,25(OH)2D3 (also known as 1α,25-dihydroxyvitamin D3 or calcitriol) has implicated ERp57 in regulation of bone-related gene transcription and mineralization (Boyan et al., 2007; Chen et al., 2016) , chondrocyte extracellular matrix (ECM) Linz et al., 2015) , protection from UV-induced damage (Sequeira et al., 2012; Song et al., 2013) , and hormone induced cellular apoptosis and differentiation . Similar to other steroidal hormones, 1α,25(OH)2D3 is capable of regulating gene expression through binding to its nuclear receptor (vitamin D receptor; nVDR), but can also activate a fast response pathway through ERp57 interaction (Nemere, Garcia-Garbi, et al., 2012) . A recent study has isolated the a′ domain of ERp57 is the probable primary domain involved in 1α,25(OH)2D3 binding (Gaucci et al., 2016) . Inhibition of E protein homodimerization ERp57 mediates reduction of E2A proteins, promoting heterodimerization of the transcription factor and preventing DNA binding and transcription of B cell differentiation genes (Markus & Benezra, 1999) .
The rapid response pathway initiated through membrane associated ERp57: 1α,25(OH)2D3 binding is carried out through modulation of transmembrane ion transport and activation of several signal transduction cascades, the full physiological implications of which have not been conclusively characterized (Boyan et al., 2007; Chen et al., 2016) . Upon binding to ERp57, 1α,25(OH)2D3-dependent activation of phospholipase A2 (PLA2) signaling stimulates protein kinase C (PKC) activation.
ERp57 overexpression promotes 1α,25(OH)2D3-induced stimulation of PLA as evidenced by rapid prostaglandin E2 (PGE2) production (Boyan et al., 2007) . In turn, PGE2-mediated phospholipase C (PLC) activation advances inositol-trisphosphate (IP3) and diacylglycerol (DAG) release, triggering calcium release from the ER and activation of membrane associated PKC and phosphorylation of mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK). MAPK/ERK Fig. 2 . Multiple binding partners and functions of ERp57. ERp57 can be localized to the ER, nucleus, cytoplasm, mitochondria and plasma membrane. In the ER, ERp57's b-b′ domains associate with the P-domain of CRT/CLNX and ERp57 a and a′ active domains mediate the catalysis of CRT/CLNX bound substrates. The observation of ERp57-mediated isomerization and release of SV40 capsid proteins has implicated ERp57's activity in viral infection. ERp57 also structurally stabilizes the MHC I PLC through formation of a disulfide bond between ERp57 and tapasin. ERp57 directly interacts with specific glycoproteins, including the growth factor PGRN, and is able to modulate their secretion. ER Ca 2+ homeostasis is regulated by ERp57's interactions with STIM1 and SERCA2b. ERp57 affects membrane proteins through both direct and indirect interactions. ERp57 mediates exposure of CRT on the cell surface, which is required for immunologic cell death. ERp57 acts as membrane receptor of 1α,25(OH)2D3 to mediate rapid responses to bioactive vitamin D including Ca 2+ release though PLA mediated phospholipase C activation. Downstream effects of ERp57: 1α,25(OH)2D3 binding also include PLA2-mediated PKC driven ADAM10 translocation to the membrane where ADAM10 mediates ectodomain shedding of TNFR1. Ionic oscillations across the plasma membrane are controlled by ERp57's stimulatory interactions with the NCC and H + K+ ATPase. ERp57 is also associated with an inhibitory effect upon internalization and degradation of EGFR, though the mechanism underlying this relationship is unclear. ERp57 is also found in STAT3 membrane rafts and cytosolic statosome complexes proposed to sequester activated STAT3, though the role(s) of these complexes is indefinite. In mitochondria, ERp57 can regulate Ca 2+ uptake and apoptotic signaling though binding with the MCU and μ-calpain, respectively. Further, cytoplasmic ERp57 can interact with p53 to inhibit p53-induced MOMP and consequent apoptosis. ERp57 also promotes the formation of mTOR complexes and may participate in mTOR redox-sensing functions. ERp57 promotes RAR-α binding to ATRA and is required for the nuclear appearance of RAR-α. ERp57 is also capable of DNA binding at target sites either alone or as a member of several protein complexes. ERp57 associates with STAT3 and NF-kB protein complexes during transit from the cytoplasm to the nucleus and participates in complex-DNA binding. ERp57 also associates with a nuclear protein complex which targets to sites of modified DNA and has been implicated in early signal for repair machinery. Nuclear ERp57 can be found bound with APE/Ref-1 and participates in reductive activation of transcription factors. Conversely, ERp57 reduction of E2A proteins promotes heterodimerization and inhibits transcriptional activity.
modulates gene expression; knockdown of ERp57 abrogates alterations in gene expression associated with the 1α,25(OH)2D3 rapid response pathway (Gaucci et al., 2016) . Apart from directly activating a signal transduction cascade as a receptor, ERp57's binding to additional substrates indirectly regulates the activity of further signals originating at the membrane, including signal transducer and activator of transcription 3 (STAT3) Sehgal et al., 2002) , epidermal growth factor (EGF) and tumor necrosis factor α (TNF-α) signaling (Yang et al., 2015 (Yang et al., , 2016 . The influx of Ca 2+ ions and activation of PKC prompted through interaction between ERp57 and 1α,25(OH)2D3 activates ADAM10 translocation to the cell surface where the metalloproteinase mediates ectodomain shedding of tumor necrosis factor receptor 1 (TNFR1). The consequent release of soluble TNFR1 restrains inflammatory TNFα signaling through reduction in receptor presentation at the membrane (Yang et al., 2015) . STATs are cytoplasmic transcription factors responsible for transcriptional regulation of genes involved in proliferation, differentiation, immune response, apoptosis and oncogenesis when activated through binding to a membrane bound receptor (Calo et al., 2003; Mui, 1999; Yu, Pardoll, & Jove, 2009 ). ERp57 associates with STAT3 plasma membrane rafts and cytosolic statosome complexes, hypothesized to constitute sites of assembly and signal integration for multiple STAT co-factors responsible for activation and shuttling STATs from the plasma membrane through the cytosol and to the nucleus Sehgal et al., 2002) . Although the function(s) of ERp57 in these plasma membrane lipid rafts and statosome complexes remains indefinite, the inhibition of cytokine activated STAT3 DNA-binding by addition of recombinant ERp57 indicates that ERp57 may be involved in inhibition of activated STAT3 signaling, an effect that could be exerted at the level of the plasma membrane (Sehgal et al., 2002) .
ERp57 impacts EGF through post-translational modification of membrane bound epidermal growth factor receptor (EGFR). EGFR activation is generally associated with anti-apoptotic signaling and deregulation of EGFR correlates with tumorigenesis Herbst, 2004) . Knockdown of ERp57 in cancer cells results in impaired phosphorylation of EGFR and increased internalization and degradation of the receptor . These observations suggest a role of ERp57 in EGFR endocytosis and activation, hypothesized to occur through ERp57's catalytic activity; however, the mechanism underlying ERp57's effect on EGF signaling remains incompletely described .
Maintenance of ionic homeostasis and signaling is critical for appropriate cellular responses and developmental processes. ERp57 has established involvement in the regulation of ionic oscillations across cellular membranes through indirect downstream effects as well as direct interactions with proton pumps. These interactions occur on the plasma membrane as well as the ER and mitochondrial membranes. In murine intestinal epithelial cells, enhanced calcium and phosphate uptake occurs upon binding of 1α,25(OH)2D3 and ERp57 and plays a role in driving PKC and MAPK/ERK activation during membrane associated receptor mediated rapid response to 1α,25(OH)2D3 Nemere, Garcia-Garbi, et al., 2012; Wang et al., 2010) . ERp57 is highly expressed and colocalizes with H+, K+-ATPase α subunit in the apical canalicular membrane of human gastric parietal cells. ERp57 positively modulates basal activity of H+, K+-ATPase through a mechanism independent of isomerase activity, chaperoning function, or expression level effects (Fujii et al., 2013 ).
An evolving understanding of manifold functionality for ERp57 in the endomembrane system is well attested by the literature. ERp57 interacts with a host of membrane proteins directly and indirectly to affect transient signaling as well as gene transcription and expression. The full mechanistic details and functional implications of relationships between ERp57 and membrane associated binding partners have not been fully characterized and may be cell type and/or co-factor dependent; regardless, existing evidence distinguishes ERp57 as a critical participant in numerous signal transduction cascades initiated at the membrane.
In mitochondria
Several laboratories have reported critical function of ERp57 in calcium flux mediated function and apoptotic signaling in mitochondria. Mitochondrial Ca 2+ uptake is regulated, in part, by ERp57's stimulatory effect on mitochondrial calcium uniporter (MCU) transcription; however, transcription of regulatory components of the MCU complex are not responsive to knockdown of ERp57 and the exact mechanism of the ERp57:MCU relationship remains to be elucidated (He et al., 2014) . Further, ERp57 associates with mitochondrial μ-calpain, a calciumdependent cysteine protease, to cleave and activate apoptosisinducing factor (AIF) (Ozaki et al., 2008) .
In cytosol
Complex formation between ERp57 and CRT on the cytosolic side of the plasma membrane is required for CRT translocation to the membrane; exposure of CRT on the cell membrane is a required for the immunogenic death observed in tumor cells (Obeid, 2008; Panaretakis et al., 2008) . As briefly reviewed above, ERp57 is an accessory scaffolding protein of both membrane rafts and cytosolic statosome complexes involved in STAT3's movement from the cell membrane, through the cytoplasm, to the nuclear membrane Ndubuisi, Guo, Fried, Etlinger, & Sehgal, 1999; Sehgal et al., 2002) . Similarly, ERp57 has been shown to co-localize with additional transcription factors during translocation between the cytoplasm and nucleus, including nuclear factor kappa beta (NF-κB) (Wu et al., 2010) , retinoic acid receptor (RAR-α) (Zhu et al., 2010) , mechanistic/mammalian target of rapamycin (mTOR) (Fingar & Blenis, 2004; Ramirez-Rangel et al., 2011; Sarbassov & Sabatini, 2005) , and tumor suppressor protein p53 (Green & Kroemer, 2009; Hussmann et al., 2015) .
ERp57 has been found co-localize with NF-κB, a transcription factor heavily implicated in immunoresponsive signaling, in the cytoplasm and nucleus of leukemia cells stimulated to undergo monocyte/macrophage differentiation (Wu et al., 2010) . This finding suggests that cytosolic ERp57 may function as a chaperone through either direct interaction with NF-κB or indirect interaction via conformational regulation within the NF-κB complex (Wu et al., 2010) . Similarly, cytoplasmic co-localization and complex formation between ERp57, RAR-α and all-trans retinoic acid (ATRA) is required for nuclear appearance of RAR-α, a transcriptional regulator implicated in multiple developmental processes (Zhu et al., 2010) . Presumably, the thiol oxidoreductase activity of ERp57 at cysteine residues of RAR-α is critical for ATRA-RAR-α binding and subsequent nuclear import of the complex (Zhu et al., 2010) . ERp57 also promotes assembly and modifies the activity of mTOR complexes, showing preferential interaction with the mTOR complex 1 (mTORC1). A reduction in mTORC1 response to insulin in ERp57 knockdown cells indicates a role of ERp57 in upstream signal detection, probably through function in the redox-sensing mechanism of mTOR (Ramirez-Rangel et al., 2011; Sarbassov & Sabatini, 2005) . ERp57 also interacts with cytoplasmic p53 via an indeterminate mechanism to inhibit p53-mediated stimulation of mitochondrial outer membrane permeabilization (MOMP) and consequent apoptosis (Fingar & Blenis, 2004; Green & Kroemer, 2009) . These findings support a role of ERp57 in modulation of mTOR and p53 mediated processes including apoptosis, cellular proliferation, redox sensing, and protein production (Fingar & Blenis, 2004; Green & Kroemer, 2009) .
These cytosolic functions of ERp57 are apparent under physiological conditions and during cellular stress in which ERp57's chaperone, redox sensing and protein folding modalities are critical to a variety of cellular processes and responses. Through cytosolic interactions, ERp57 directly and indirectly modulates the activity of multiple pathways involved in cellular stress response, cellular differentiation, autophagy, apoptosis, and immune response. Although we have reviewed only a subset of the interactions observed in the cytoplasm, it is clear that the effects of ERp57's presence in the cytoplasm are manifold.
In the nucleus
In addition to the C-terminal QEDL ER retention/retrieval sequence, ERp57 also contains a KKKK nuclear location sequence (Adikesavan, Unni, & Jaiswal, 2008) . The presence of ERp57 in the nuclear compartment was first reported by immunofluorescence in 1993 (Ohtani, Wakui, Ishino, Komatsuda, & Miura, 1993) and has since been independently verified by multiple investigators. Stimulation of various mammalian cell lines with TNF-α, 1α,25(OH)2D3, or phorbol 12-myristate 13-acetate has been demonstrated to induce nuclear translocation of cytoplasmic and/or membrane localized ERp57 to the nucleus (Grindel et al., 2011; Rohe et al., 2005; Wu et al., 2010) . Nuclear ERp57 has been shown to directly interact with DNA, influence the activation and DNA binding of various transcription factors and protein complexes, and participate in the nuclear import and export of proteins (Aureli et al., 2013; Coppari et al., 2002; Grillo et al., 2006) .
In DNA binding, ERp57 targets to regulatory regions for genes involved in cellular adhesion, intracellular traffic, and cellular stress response (Aureli et al., 2013; Chichiarelli et al., 2007; Grillo et al., 2006) . The presence of nuclear ERp57 does affect the transcription of target regions; however, ERp57 does not bind to DNA with the affinity typical of a transcription factor (Aureli et al., 2013) . Importantly, ERp57 has been isolated as a component of several multiprotein nuclear complexes engaged in DNA binding which may dictate nuclear functionality. ERp57 associates with a nuclear protein complex that targets to modified DNA in cells with defective DNA mismatch repair (Krynetski et al., 2003) wherein ERp57 is able to phosphorylate H2AX, indicating a role of ERp57 in early response to the appearance of double-strand breaks, potentially involved in targeting DNA repair machinery to sites of damage and/or activating apoptosis (Krynetskaia, Phadke, Jadhav, & Krynetskiy, 2009; Podhorecka, Skladanowski, & Bozko, 2010) . ERp57 is present in STAT3-DNA complexes and inhibition of ERp57 can reduce STAT3-DNA binding (Eufemi et al., 2004) . ERp57 is also capable of indirectly influencing gene expression by participating in redox-mediated activation of transcription factors. DNA repair enzyme and transcriptional regulator APE/Ref-1 associates with ERp57 in the nucleus and the putative functional implications of ERp57:APE/Ref-1 association include cooperative reduction of transcription factors including activator protein 1 (AP-1) and related downstream effects including protection against oxidative stress induced apoptosis (Grillo et al., 2006) . ERp57 also has negative regulatory effects on transcriptional activators exemplified through its reduction of E2A proteins, promoting heterodimerization of the transcription factor and thereby preventing DNA binding and transcription of B cell differentiation genes (Markus & Benezra, 1999) . These studies suggest that stress-responsive ERp57 may function to affect transcription of genes relevant to cell survival and differentiation either through direct or indirect interaction with DNA targets and/or transcriptional regulators.
Associations of ERp57 dysregulation and pathologies
The evidence for importance of ERp57 in multiple regulatory pathways at the cellular and molecular levels, reviewed above, supports supposition that de-regulation of ERp57 could be a feature of multiple disease etiologies in which these pathways are disrupted. In fact, altered expression levels of ERp57 have been associated multiple diseases affecting diverse organ systems. Here, we have briefly reviewed the relationships between ERp57 physiological functions and proposed and/or evidenced dysfunction in disease (summarized in Table 2 ).
Cancer
ERp57 is variably dysregulated in many forms of cancer and aberrant ERp57 expression has been evaluated clinically as a prognostic marker; either upregulation or downregulation of ERp57 can correlate with poor prognosis, depending on the affected tissues (Celli & Jaiswal, 2003; Choe et al., 2015; Chung et al., 2013; Gaucci et al., 2013; Leys et al., 2007; Liao et al., 2011; Ogino et al., 2003; Wise et al., 2016; Zhu et al., 2010 Zhu et al., , 2016 . The association between bidirectional alteration in ERp57 expression and development and prognosis of many different cancers indicates potential involvement in the complex cellular and molecular processes underlying the etiological heterogeneity of cancer.
ERp57 has been evaluated mechanistically and as a therapeutic target in cancer progression and treatment and knockdown of ERp57 in various cancer cell lines instigates diverse alterations to the pathways involved in ERp57's physiological functions. ERp57 has been implicated as a potential target for therapeutic modulation of apoptotic signaling and metastasis via its indirect regulation of EGFR Porter, Fritz, & Depew, 2010) , mediation of rapid response to 1α,25(OH)2D3 , association with the MHC PLC (Santana-Codina et al., 2013), binding CRT (Panaretakis et al., 2008) , activation of the UPR (Hussmann et al., 2015) , mTOR signaling (Fingar & Blenis, 2004; Ramirez-Rangel et al., 2011; Sarbassov & Sabatini, 2005) , and direct DNA binding (Aureli et al., 2013; Grillo et al., 2006 ).
ERp57's receptor-ligand interactions, as well as its associations with protein complexes, have been implicated in cancer cell proliferation. Overexpression of ERp57 promotes proliferative signaling due, in part, to ERP57-mediated stabilization of mTORC1 and ERp57 may have a further role as a component of mTORC1's redox sensing machinery (Ramirez-Rangel et al., 2011) . EGFR is overexpressed in triple negative breast cancer cells and activation of EGFR is associated with antiapoptotic singling . Knockdown of ERp57 in MDA-MB-231 cells and in cervical cancer cells results in impaired phosphorylation and increased degradation of the receptor Porter et al., 2010) . Similarly, knockdown of ERp57 in MCF-7 breast cancer cells reveals increased cellular sensitivity to vitamin D-mediated anti-proliferative signaling . The shared effects of ERp57 overexpression on cell survival via interactions with EGFR, 1α,25(OH)2D3, and mTOR-mediated proliferative signaling in multiple cancerous cell lines indicates that targeted depletion of ERp57 may be a candidate for expedient development of new therapies.
Study of correlations between ERp57 expression levels and prognoses has revealed that ERp57 also participates in disease progression and metastasis of multiple cancers. ERp57 is upregulated during anchorageindependent growth and metastasis of estrogen receptor negative cells and epithelial ovarian cancer cells (Wise et al., 2016; Zhu et al., 2016) . ERp57 overexpression also coincides with underexpression of MHC class I molecules resulting in a negative effect upon MHC PLC stability and antigen presentation, a key event in breakdown of immune surveillance and tumor cell invasion (Garrido et al., 1993; Marincola, Jaffee, Hicklin, & Ferrone, 1999; Santana-Codina et al., 2013) . Further, ERp57 is required for immunologic cell death through mediating exposure of CRT on the cell surface (Panaretakis et al., 2008) . In epithelial ovarian cancer, low expression of Dicer, an RNAase essential for RNA interference, is a marker of metastasis and poor prognosis and has been linked to increased ERp57 expression (Zhu et al., 2016) . Knockdown of ERp57 in Dicer-deficient cells is able to abrogate increased cellular proliferation and migration, presumably through loss of ERp57's downstream effects on STAT3 and Wnt signaling (Liao et al., 2014; Xie et al., 2004; Zhu et al., 2016) . These observations indicate that ERp57 may participate in changes to cancer cell adhesion, immunogenicity and invasion through multiple pathways.
ERp57 has been singled out as a marker of chemoresistance in several cancers (Choe et al., 2015; Cicchillitti et al., 2009; Hussmann et al., 2015) . The requirement of ERp57 for CRT presentation and efficient MHC PLC activity suggests that a defect in these functions could underlie ERp57 is believed prevent aggregation of amyloid β under physiological conditions (Erickson et al., 2005) . Activation of ERp57 results in axonal regrowth, an overall reduction of AD neuropathology and increased performance on object recognition tasks in murine models of AD (Tohda et al., 2012) . Autoantibodies against GFAP, a protein that is upregulated during reactive gliosis (Muramori, Kobayashi, & Nakamura, 1998; Pike, Cummings, & Cotman, 1995; Wang, Cioffi, Cull, Dong, & Fortune, 2002; Wang, Tay, & Ng, 2000; Wilding et al., 2015) , have been shown to exert a protective effect against oxidative stress via cell-surface interaction with ERp57 (Wilding et al., 2015) . Peripheral nerve injury Overexpression of ERp57 in transgenic mice facilitates peripheral nerve regeneration after injury (Castillo et al., 2015) . Prion-protein related disorders ERp57 is upregulated, probably as a defensive response against misfolded prion protein toxicity, in CJD (Hetz et al., 2005) . ERp57 likely mediates steady state levels of both wild-type and prion-related disorder (PrD)-related mutant protein indicating a limited role of ERp57 deficiency to protective effect against ER stress susceptibility (Sepulveda, Rozas, Hetz, & Medinas, 2016; Torres et al., 2015 ). Huntington's disease ERp57 stimulation of MOMP is implicated in neurodegenerative diseases that feature aberrant cytosolic protein aggregation and several molecules reduce huntingtin protein mediated toxicity through inhibition of ERp57 and/or PDI (Hoffstrom et al., 2010) Musculoskeletal system development and maintenance Heterozygous PDIA3 knockout mice PDIA3 ± mice exhibit extensive abnormalities in bone morphometry and quality .
Chondrocyte-specific PDIA3 knockout mice Loss of ERp57 in chondrocytes causes increased ER stress and activation of the unfolded protein response (UPR) leading to elevated ER-stress-induced apoptosis and inflammation (Linz et al., 2015) .
Murine osteoblast precursor cells
In MC3T3-E1 cells, ERp57 participates in mediation of crosstalk between BMP-2 and 1α,25(OH)2D3 in directing mineralization and osteoblastic differentiation . In murine embryoid bodies, ERp57 expression level changes are associated with osteogenic differentiation further supporting a role in osteoblastogenesis (Olivares-Navarrete et al., 2012).
Murine enterocytes
The ERp57:1α,25(OH)2D3 interaction mediates regulation of Ca 2+ in mammalian intestinal cells Nemere, Garcia-Garbi, et al., 2012) , however the role of ERp57 in overall calcium metabolism and the potential effects in bone remain unexplored. Human aortic smooth muscle cells Ca 2+ influx following ERp57:1α,25(OH)2D3 binding induces cell surface translocation of ADAM10 and subsequent ectodomain cleavage of TNFR1 potentially inhibiting inflammatory signaling through neutralization of TNFα (Yang et al., 2015) .
Digestive system and accessory organs HEK293 cells expressing H+,K+-ATPase ERp57 controls basal activity of H+, K + −ATPase (Fujii et al., 2013) , which regulates gastric acid secretion. H+,K+ ATPase is therapeutically targeted by protein pump inhibitors used in the treatment of various acid diseases (Sachs et al., 2007) . Murine intestinal cells and Sprague-Dawley rat kidney cells 1α,25(OH)2D3:ERp57-mediated regulation of ion pump activity has been implicated as a key regulator of calcium, sodium and phosphate flux in intestinal cells in response to vitamin D stimulation Nemere, Garbi, & Winger, 2015; Prins et al., 2011; Wyse et al., 2002) (continued on next page) the establishment of chemoresistent cell populations. ERp57's associations with various nuclear complexes have also been demonstrated to correlate with chemoresistance. In ovarian cancer cells, ERp57 complexes with and exerts conformational modification on β-actin and is associated with mitotic defects and the development of drug resistance (Cicchillitti et al., 2010) . Moreover, sensitization of radioresistent laryngeal cancer cells through inhibiting ERp57-STAT3 complex mediated activation of myeloid leukemia cell differentiation protein (Mcl-1) has been demonstrated (Choe et al., 2015) . Similarly, inhibition of ERp57 in HCT116 colon cancer cells has been shown to bolster ER-stress induced apoptosis with concomitant chemotherapy and irradiation treatment through p53-mediated PKR-like ERkinase (PERK) UPR activation. This study further revealed that ERp57 activates proliferative signaling via mTOR in colon and MDA-MB-231 breast cancer cells. Notably, however, basal-like breast cancer cells did not display increased apoptosis following ERp57 knockdown (Hussmann et al., 2015) . Accordingly, the involvement of ERp57 in the development of drug resistance warrants further study to more fully describe mechanisms and disease specificity.
ERp57 also engages in direct interactions with DNA at sequences compatible with regulatory function (Aureli et al., 2013; Grillo et al., 2006) . Silencing of ERp57 in melanoma cells results in significantly downregulated expression of target genes involved in DNA repair and stress response (Aureli et al., 2013) . However, ERp57 does not bind to DNA with the affinity typical of a transcription factor and the roles of ERp57's DNA binding capability in transcriptional regulation are not entirely clear. Current evidence suggests that ERp57 takes part in the activation of transcription factors, including APE/Ref-1-ERp57 mediated activation of AP-1 (a gene implicated in protection against oxidative stress induced apoptosis) through participation in nuclear protein complexes. (Aureli et al., 2013; Grillo et al., 2006) . The observations of ERp57-Ref-1 nuclear translocation following oxidative stress (Grillo et al., 2006) and of APE/Ref-1's association with MSH6, a target of ERp57 producing a component of the DNA repair machinery, offer support for a role of ERp57-containing protein complexes in transcriptional regulation through cooperative activation of transcriptional regulators. A role of ERp57 in early response to DNA modification has also been unveiled through observation of ERp57-mediated phosphorylation of H2AX following chemotherapy, generating λH2AX -a sensitive marker of genotoxicity (Chichiarelli et al., 2007; Krynetski et al., 2003) . Accordingly, ERp57 may directly and indirectly participate in activation of cell survival, DNA repair, and/or pro-apoptotic signals through DNA binding and transcriptional modulation in conditions of oxidative stress and DNA damage.
The role of ERp57 in cancer is complex and disease dependent. ERp57 is expressed at levels outside of the physiological range in several cancers and targeted knockdown or overexpression of ERp57 in cancerous cell lines has a variable impact on many of pathways involved in apoptosis, proliferation, and motility. Further, ERp57 is an upstream mediator of key signaling pathways involved in tumorigenesis, invasion, cell proliferation, apoptosis etc. and has also been shown to modulate activity of pro-survival transcription factors in melanoma and cervical cancer cell lines. ERp57's value as a marker for disease, prognosis, and chemoresistance in various cancers may highlight the utility of ERp57 expression levels in evaluation and/or supplementation of therapeutic agents for cancer treatment. For example, upregulated expression of ERp57 has been reported in acute myeloid leukemia cells and treatment with shikonin, a plant extract with anticancer effects, results in downregulation of ERp57 and inhibition of ERp57 increases shikonininduced apoptosis in primary and established human leukemia cell lines (Trivedi et al., 2016) . Collectively, ERp57 may be a powerful molecular target in the development of new cancer therapies. However, as indicated by the association between ERp57's varied expression levels and different prognoses in different carcinomas, targeted modulation of ERp57 can have contrasting effects upon various signaling pathways implicated in disease establishment and progression and these multilevel effects should be considered during therapeutic development. Knockdown of ERp57 is associated with increased autophagic failure-induced cell death in pancreatic β cells (Yamamoto et al., 2014) .
Human renal fibroblasts
In TK173 cells, elevated ERp57 secretion is strongly associated with ECM production and inhibition of ERp57 impairs accumulation of ECM (Dihazi et al., 2013) . Human patients and Col4a3 knockout renal fibrosis model mice Excretion of ERP57 in urine serves as a diagnostic marker for renal fibrosis during the early stage of the disease (Dihazi et al., 2013) . Streptozotocin-induced Type 2 diabetic rats Diabetic rats exhibit a reductive shift in and downregulated function of ERp57 (Nardai et al., 2005) . Rat β cell model of permanent neonatal diabetes Altered redox state of ERp57, co-occuring with defective insulin secretion and reduced proliferation occurs after knockdown of EIF2AK3 in rat β cells (Feng, Wei, Gupta, McGrath, & Cavener, 2009) .
Human liver cells
In a L02 cell model of NAFLD, ERp57 protective against fatty acid induced steatosis and apoptosis (Zhang et al., 2015) . Sprague Dawley rats and leptin-deficient mice Gastric mucosa protein level of ERp57 is downregulated and ERp57 is dephosphorylated in fasting rats; this redox shift could be inhibited by leptin and leptin could induce gastric mucosa ERp57 mRNA expression in rats and fasted leptin-deficient mice (Bravo et al., 2011) [143] . Inducible knockout of ERp57 in mice Knockout of ERp57 correlates with reduced body fat, coincident with an extended lifespan. Estradiol mediated competitive inhibition of 1α,25(OH)2D3:ERp57 binding has been implicated in ERp57's role in body fat homeostasis (Nemere et al., 2015) however, the estradiol:ERp57 interaction requires further study.
Respiratory system Respiratory epithelial cells ERp57 and activating transcription factor 6 (ATF6), an ER stress transducer (Hetz, 2012) , are upregulated upon in vitro stimulation with house dust mite (Hoffman et al., 2013) . Knockdown of ATF6 in these cells alleviates allergen-induced ERp57 upregulation and cell death associated with HDM exposure (Hoffman et al., 2016) . Deletion of ERp57 in lung epithelial cells has further demonstrated diminished immune response upon HDM stimulation coincident with a reduction in multiple markers of immune response (Hoffman et al., 2016) . ERp57 knockdown mice Knockdown of ERp57 in asthmatic mice is correlated to reduced ER stress in response to allergen challenge (Hoffman et al., 2013) .
Respiratory epithelial cells
ERp57-depletion and inhibition confers resistance to Burkholderia cenocepacia infection in epithelial cells (Pacello, D'Orazio, & Battistoni, 2016) .
Other Sertoli cells ERp57 may support spermatogenesis and germ cell survival through mediating nuclear localization of RARα (Zhu et al., 2010) Platelets ERp57 is secreted and localizes to the platelet thrombus to recruit platelets and facilitate fibrinogen binding and fibrin deposition (Cui et al., 2015; Zhou et al., 2014) . The overlap in expression patterns and potential functional redundancy of PDI proteins in platelet function suggests that targeting one or more of these proteins could provide useful intervention in pathological thrombosis.
Neurodegenerative diseases
Aggregation of misfolded proteins is a central feature in the pathology of many neurodegenerative diseases including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's Disease (HD) and Creutzfeldt-Jakob disease (CJD). ER stress and activation of the UPR upon accumulation of misfolded and/or nascent proteins are common features implicated in the cellular pathology of these diseases. However, the cumulative effect of UPR activation is dependent on the duration and integration of cell survival and apoptotic signals and the role of the UPR in neurodegeneration is complex; with evidence for both protective and detrimental effects of UPR activation commonly observed in the same disease. Notably, activation of the UPR features increased recruitment of PDI family members to facilitate protein folding or trigger apoptosis. An increasing number of studies have focused on the role of ERp57, revealing potential dual functionality as a protective and proapoptotic factor, in neurodegeneration.
The identification of ERp57 as a progranulin (PGRN)-interacting protein (Almeida et al., 2011) has drawn attention to a role of ERp57 in the mechanisms underlying the relationship between progranulin insufficiency and neurodegenerative and peripheral proteopathies including FTD, a common form of dementia that has been strongly linked to mutations in the PGRN gene (GRN) (Baker et al., 2006; Cruts et al., 2006; van der Zee et al., 2007) . ERp57 directly interacts with PGRN to regulate PGRN secretion and may be a powerful target for therapeutic modulation in conditions that feature PGRN deficiency (Almeida et al., 2011) . Further, Gaucher's disease (GD), a lysosomal storage disease with variable neurological involvement, has recently been associated with the appearance of several GRN variants and low serum levels of PGRN . Mechanistically, PGRN recruits HSP70 to form a complex which binds to and acts as a chaperone of lysosomal enzyme β-glucocerebrosidase (GCaase), mutations of which are causative of GD, and impedes aggregation of mutated GCase ). PGRN's ability to interact with and disaggregate lysosomal enzymes suggests that modulation of PGRN secretion through targeting ERp57 might also represent a new therapeutic strategy in lysosomal storage diseases.
ALS is characterized by degeneration of motor neurons in the brain and spinal cord (Kent-Braun, Walker, Weiner, & Miller, 1998) . Several gene variants have been isolated as contributory or causative factors in cases of familial and sporadic ALS and the genes most heavily implicated include C9orf72 and superoxide dismutase 1 (SOD1); revealing a complex role of elevated ER stress response in the cellular pathology of ALS (Dafinca et al., 2016; Nishitoh et al., 2008; Wang, Popko, & Roos, 2011) . Moreover, a recent screen for relevant mutations in PDIs among ALS patients revealed several missense mutations and single nucleotide polymorphisms (SNPs) in PDIA3/ERP57 potentially affecting CRT/CLNX binding (Gonzalez-Perez et al., 2015) . Longitudinal analysis of protein expression during ALS disease course reveals that ERp57 is strongly upregulated in the cerebrospinal fluid and peripheral blood of ALS patients and ERp57 level is highly correlated with disease severity (Atkin et al., 2008; Nardo et al., 2011) . These findings suggest that ERp57 may be upregulated to combat disrupted protein folding in ALS and that sustained elevation and/or dysfunction of ERp57 may aggravate neuronal apoptosis.
ERp57 is also demonstrates a stimulatory effect on axonal regrowth in several neurodegenerative diseases. AD is a proteopathy in which extracellular aggregates of β-amyloid exert a cytotoxic effect on surrounding neurons. Under physiological conditions, ERp57 is believed to bind amyloid β (Aβ) through interaction with CRT and thereby prevent aggregation (Erickson et al., 2005) . Pharmacological stimulation of cortical and hippocampal axonal regrowth in transgenic mice co-expressing multiple AD related mutations is dependent upon activation of ERp57 and activation of ERp57 results in an overall reduction of AD neuropathology and increased performance on object recognition tasks in these murine models (Tohda et al., 2012) . Potential evidence for ERp57's role in axonal regeneration has also been indicated in degenerative disease affecting the peripheral nervous system. Notably, peripheral neuropathy is variably reported as an aspect of PD and overexpression of ERp57 in transgenic mice facilitates peripheral nerve regeneration after injury (Castillo et al., 2015) .
Additional roles of ERp57 in aspects of neurodegenetation have been described. Autoantibodies against glial fibrillary acidic protein (GFAP), a protein that is upregulated during reactive gliosis in AD (Muramori et al., 1998; Pike et al., 1995) and glaucoma (Wang et al., 2000 (Wang et al., , 2002 Wilding et al., 2015) , have been shown to exert a protective effect against oxidative stress via cell-surface interaction with ERp57 (Wilding et al., 2015) . In CJD, upregulated ERp57 is believed to be a defensive response against misfolded prion protein toxicity (Hetz et al., 2005) . However, recent characterization of the role of ERp57 in mediating steady state levels of both wild-type and prion-related disorder (PrD)-related mutant protein has suggested that ERp57 deficiency may contribute to prion protein folding but may not contribute to protective effect against ER stress susceptibility (Sepulveda et al., 2016; Torres et al., 2015) . Importantly, the ability of several molecules to inhibit mutant huntingtin protein mediated toxicity through inhibition of ERp57 and/or PDI highlights that PDIs can exert pro-apoptotic effects through stimulation of MOMP in neurodegenerative diseases that feature aberrant cytosolic protein aggregation (Hoffstrom et al., 2010) .
In summation, ERp57 has been proposed as an important mediator of cellular response to endoplasmic reticulum stress during the disease course of several neurodegenerative disorders. The conventional role of ERp57 as a disulfide isomerase and chaperone, as well as its role in signal transduction at the cell membrane, has been implicated in mediation of ERp57's protective effects. Upon ER stress, ERp57 may be upregulated as part of a protective response to facilitate folding of aggregated proteins and restore cellular proteostasis. At the same time, concentrated ERp57 is able to stimulate apoptosis through MOMP. Notably, ERp57 is a selective foldase responsible for interaction with only a subset of potential protein aggregates. Additional studies are required to more fully define the in vivo importance of ERp57's activity in response to ER stress as well as other subcellular localizations in neurodegenerative disease. ERp57 could prove a useful target for modulation of apoptosis in the nervous system.
Musculoskeletal system
Little is known about the direct involvement of ERp57 in the cellular pathology of musculoskeletal diseases. Notably however, ERp57's physiological role as a vitamin D receptor indicates a critical role in skeletal development. Further, ERp57's interactions with SERCA2b and indirect influence on TNFR1 signaling suggest that ERp57 activity could be therapeutically modulated in musculoskeletal disorders.
1α,25(OH)2D3 is a key factor in musculoskeletal development and homeostasis through promotion of chondrocyte proliferation, maturation, hypertrophy and osteoblast differentiation (Enishi et al., 2014; Linz et al., 2015; Yang, Tsang, Tang, Chan, & Cheah, 2014) . As reviewed above, ERp57 acts as a rapid response 1α,25(OH)2D3 receptor. Heterozygous (PDIA3 ± ) PDIA3 knockout mice exhibit abnormalities in bone morphometry and quality similar to those observed in mice deficient in nuclear steroid hormone vitamin D receptor (nVDR
), the canonical 1α,25(OH)2D3 receptor involved in transcriptional regulation during bone development . Further, chondrocytespecific PDIA3 knockout mice exhibit increased ER stress and activation of the UPR leading to elevated ER-stress-induced apoptosis and inflammation (Linz et al., 2015) . Expression of ERp57 and nVDR are both believed to participate in osteogenic commitment and expression levels exhibit opposing changes during osteogenic differentiation in murine embryoid bodies, suggesting that differential modulation of 1α,25(OH)2D3 receptors may work in concert and/or independently to dictate stage specific differentiation signals (Olivares-Navarrete et al., 2012) .
The ERp57:1α,25(OH)2D3 interaction can further influence bone and cartilage development via additional mechanisms. In matrix vesicles of growth zone chondrocytes, ERp57: 1α,25(OH)2D3 binding similarly results in activation of PLA2, consequent degradation of membrane integrity and release of matrix metalloproteinase 3 (MMP-3) and activation of TGF-β (Boyan et al., 2007 (Boyan et al., , 2012 Chen et al., 2010) . TGF-β is able to transcriptionally regulate ERp57 expression through the canonical mothers against decapentaplegic homolog 3 (SMAD3) signaling (Rohe, Safford, Nemere, & Farach-Carson, 2007) . A recent study has further revealed that ERp57 participates in mediation of crosstalk between bone morphogenetic protein-2 (BMP-2) and 1α,25(OH)2D3 in directing mineralization and osteoblastic differentiation . The association of ERp57 with TGF-β and BMP-2, vital pathways capable of coordinating signal integration during skeletal development (Chen, Deng, & Li, 2012) , suggests that the dependence of rapid response to 1α,25(OH)2D3 upon ERp57 is may not be limited to the latter's function in initial signal transduction. Additionally, the observation of ERp57:1α,25(OH)2D3 mediated regulation of Ca 2+ in mammalian intestinal cells Nemere, Garcia-Garbi, et al., 2012) raises the need for further research into a role of ERp57 in calcium metabolism and potential effects in bone. The relationship between ERp57, bioactive vitamin D, and activation of bone regulatory pathways supports additional study concerning the involvement of ERp57 in bone development, particularly in vitamin Drelated disorders.
ERp57 may also indirectly restrain inflammatory TNFα signaling through release of soluble TNFR1. TNFα signaling is heavily implicated in numerous inflammatory disorders affecting multiple organs systems including bone and muscle. ERp57:1α,25(OH)2D3 mediated activation Ca 2 + influx triggers ADAM10 translocation to the cell surface where the metalloproteinase mediates cleavage of the extracellular portion of TNFR1. The release of soluble TNFR1 restrains inflammatory signaling through neutralization of TNFα and reduction in receptor presentation at the membrane (Yang et al., 2015) . Notably, TNFR2, a TNFα receptor demonstrated to mediate a protective pathway in several physiological and disease processes (Defer, Azroyan, Pecker, & Pavoine, 2007; Dong et al., 2016; Wei et al., 2014) , including musculoskeletal diseases (Tang et al., 2011; Williams, Wang, Thurner, & Liu, 2016; Zhao, Tian, Frenkel, & Liu, 2013) , does not undergo cleavage in this process (Yang et al., 2015 (Yang et al., , 2016 . Several anti-TNFα therapies are used clinically for treatment of musculoskeletal diseases including rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis (Atzeni et al., 2015; Braun et al., 2006; Gorman, Sack, & Davis, 2002; Maksymowych et al., 2012) . However, TNFα inhibitors are expensive, not all patients appropriately respond to available anti-TNFα therapies and some approaches target both inflammatory TNFR1 and protective TNFR2 signaling (Van Hauwermeiren, Vandenbroucke, & Libert, 2011; Wei, Buza, and Liu, 2016) . Accordingly, the development of alternative biologics is imperative and further study of ERp57 may present new targets for restraining inflammatory TNFα signaling. Importantly, our group has demonstrated effective amelioration of several musculoskeletal conditions via treatment with a non-oncogenic progranulin derivative, termed Atsttrin, capable of competitively inhibiting TNFR1:TNFα signaling coincident with targeted activation of TNFR2 (Tang et al., 2011; Wei, Hettinghouse, and Liu, 2016; Zhao et al., 2015) . Moreover, direct interaction between ERp57 and PGRN has been reported (Almeida et al., 2011) and the overall significance of the PGRN:ERp57 in inflammatory signaling observed in musculoskeletal conditions remains to be thoroughly expounded. ERp57 represents another potentially powerful molecular target that could be co-opted to provide a new avenue for selective inhibition of inflammatory TNFR1 signaling while the interaction between PGRN and ERp57 could be exploited in stimulation of protective TNFR2 signaling.
Digestive system and accessory organs
The importance of ERp57's role as a modulator of ionic flux has been particularly attested within the digestive system. 1α,25(OH)2D3:ERp57-mediated regulation of ion pump activity has been implicated as a key regulator of calcium and phosphate flux in intestinal cells in response to vitamin D stimulation Nemere et al., 2015; Prins et al., 2011) . In murine intestinal cells, Ca 2+ transport initiated upon 1α,25(OH)2D3:ERp57 binding is dependent upon downstream activation of the PKA pathway while phosphate uptake is believed to be partially dependent on PKA activation in mammalian cells (Nemere, Garcia-Garbi, et al., 2012) . Calcium uptake is a major mediator of cellular and subcellular signaling and calcium balance is necessary for the maintenance of multiple systems. The participation of ERp57 in 1α,25(OH)2D3-induced Ca 2+ movement and downstream effects suggests that ERp57 may have some role in maintaining calcium homeostasis however more research is warranted to determine the overall importance of ERp57-mediated rapid response to intestinal calcium absorption and calcium metabolism. ERp57 has also been proposed to modulate basal activity of H +, K+-ATPase (Fujii et al., 2013) . H+, K+-ATPase activity in the stomach regulates acid secretion H+,K+ ATPase is therapeutically targeted by protein pump inhibitors used in the treatment of various acid diseases (Sachs et al., 2007) . Potassium-chloride cotransporter 4 (KCC4), another ion pump implicated in gastric acid secretion, is co-expressed with and K+-Cl − cotransport via KCC4 has been functionally linked to H +, K +-ATPase activity (Fujii et al., 2009 (Fujii et al., , 2013 ERp57's potential role in the modulation of KCC4 has not been elucidated. ERp57 also stimulates sodium uptake through interaction with the cytoplasmic C-terminal domain of plasma membrane of the Na + -Cl − cotransporter (NCC) in mammalian kidney cells and ERp57 deficiency co-occurs with reduced sodium uptake, demonstrating functional significance (Wyse et al., 2002) . ERp57 has been implicated in models of several metabolic diseases including diabetes (Feng et al., 2009; Nardai, Korcsmaros, Papp, & Csermely, 2003; Yamamoto et al., 2014) , nonalcoholic fatty liver disease (NAFLD) (Zhang et al., 2015) , and obesity (Bravo et al., 2011) . Knockdown of ERp57 is associated with increased autophagic failureinduced cell death in pancreatic β cells (Yamamoto et al., 2014) . Elevated ERp57 secretion is strongly associated with ECM production in animal models of renal fibrosis and inhibition of ERp57 impairs accumulation of ECM (Dihazi et al., 2013) . Altered redox state distributions have been reported in streptozotocin-induced diabetic rats, which exhibit a reductive shift in and downregulated function of ERp57 (Nardai et al., 2003) ; knockdown of EIF2AK3, encoding PERK, in a rat β cell model of permanent neonatal diabetes is also associated with altered redox state of ERp57, defective insulin secretion, and reduced proliferation (Feng et al., 2009 ). In NAFLD, ERp57 serves a protective role against fatty acid induced steatosis and apoptosis (Zhang et al., 2015) . Further, in fasting rats gastric mucosa protein level of ERp57 is downregulated and is predominately dephosphorylated; this redox shift could be inhibited by leptin, a hunger-inhibiting hormone associated with obesity, and leptin could induce gastric mucosa ERp57 mRNA expression (Bravo et al., 2011) . Leptin activity is at least partially dependent on STAT3 activation and ERp57 is believed to regulate STAT3 (Choe et al., 2015; Guo et al., 2002; Ndubuisi et al., 1999; Villanueva & Myers, 2008) . Interestingly, inducible knockout of ERp57 in mice correlates with reduced body fat, coincident with an extended lifespan exhibiting some sexual dimorphism, relative to wild-type littermates (Nemere et al., 2015) . The effect of ERp57 upon lifespan and body fat homeostasis may be, at least in part, attributable to estradiol mediated competitive inhibition of 1α,25(OH)2D3:ERp57 binding leading to lipid droplet accumulation in particular cellular environments of wildtype mammals, however, the estradiol:ERp57 interaction requires further study (Nemere et al., 2015) . These studies demonstrate that ERp57 redox state may be differentially altered during ER stress associated with metabolic diseases affecting the digestive system accessory organs. More broadly, ERp57 may have a role in energy modulation and nutrient availability, clarification of which is necessary to better understand the comprehensive role of ER proteins in metabolic disease.
Respiratory system
Pathological features of allergic asthma, including inflammation, airway fibrosis, and airway hyper-responsiveness, are in part attributable to allergen-induced upregulation of protein synthesis contributory to activation of the UPR and ER stress induced cell death (Gregory & Lloyd, 2011; Hoffman et al., 2013; Lambrecht & Hammad, 2012; Ryu et al., 2013; Tabas & Ron, 2011) . ERp57 and activating transcription factor 6 (ATF6), an ER stress transducer (Hetz, 2012) , are upregulated upon in vitro stimulation of human bronchiolar and nasal epithelial cells with house dust mite (HDM), a common allergen (Hoffman et al., 2013) . Knockdown of ATF6 in these cells alleviates allergen-induced ERp57 upregulation and cell death associated with HDM exposure (Hoffman et al., 2016) . Knockdown of ERp57 in asthmatic mice is correlated to reduced ER stress in response to allergen challenge (Hoffman et al., 2013) . A recent study employing targeted deletion of ERp57 in lung epithelial cells has further demonstrated diminished immune response upon HDM stimulation coincident with a reduction in multiple relevant inflammatory T cell activators, diminished functionality of pro-fibrotic growth factors, and reduced disulfide bridges and oligomerization of chemotactic proteins and apoptotic factors, respectively (Hoffman et al., 2016) . These findings provide strong evidence for the involvement of ER stress-dependent responses in at least some asthmatic pathologies and that ERp57 is heavily involved in regulation of allergen response. Accordingly, ERp57 may be a useful target in the development of new biologics for treating allergic asthma.
ERp57 has also recently been revealed as a potential facilitator of Burkholderia cenocepacia, a pathogen connected to poor prognosis of cystic fibrosis, infection and adhesion (Pacello et al., 2016) . In this study, ERp57-depleted epithelial cells were more resistant to bacterial infection, ERp57 antibody reduced adhesion and infection, and inhibition of ERp57 was associated with reduced inflammatory response in infected cells (Pacello et al., 2016) . Notably, however, the mechanism of Burkholderia infection is not fully understood and may be strain specific. Regardless, ERp57 inhibition may present a promising avenue for preventing or treating pathogenic lung infection.
Other diseases and conditions
Platelets express number of PDI family proteins including PDI, ERp57, ERp72, and ERp29 (Holbrook et al., 2010) . ERp57 is involved in regulation of normal platelet aggregation, integrin activation and signaling (Essex & Li, 1999; Lahav et al., 2002) . Upon vascular injury, ERp57 is secreted and localizes to the platelet thrombus to recruit platelets and facilitate fibrinogen binding and fibrin deposition (Cui et al., 2015; Zhou et al., 2014) . The overlap in expression patterns and potential functional redundancy of PDI proteins regarding platelet function suggests that targeting one or more of these proteins could provide useful intervention in pathological thrombosis. The roles of PDIs in platelet function must be further elucidated in order to identify the optimal PDI target for therapeutic modulation, however, recent evaluation of a ERp57-inhibitor has generated promising results (Cui et al., 2015) .
Conclusions and perspectives
An increasing number of studies have demonstrated that ERp57 is a multifunctional protein implicated in numerous physiological processes and disease states. ERp57's unique structure, multiple subcellular localizations, and ubiquitous but variable and specific expression patterns in different tissues, each vitally contribute to the complexity of ERp57's physiologic functionality. Accordingly, alteration in ERp57 through structural and/or regulatory modification may promote development of various diseases. In fact, available literature has linked dysregulation of ERp57 expression to developmental abnormalities of bone and cartilage, cancer, neurodegeneration, asthma, bacterial infection, and metabolic disorders; recent work has also indicated the ability of viral appropriation of ERp57's isomerase functionality during infection. Currently, the mechanisms underlying ERp57's associations with numerous pathological states are not fully understood and additional work is required to optimize the extensive therapeutic potential of targeting ERp57. However, ERp57 is clearly represents a promising target in translational research.
